InvestorsHub Logo
Followers 53
Posts 1783
Boards Moderated 0
Alias Born 03/22/2015

Re: None

Thursday, 05/02/2019 5:51:51 PM

Thursday, May 02, 2019 5:51:51 PM

Post# of 403117
Calcium Channel Blocker Flops in Parkinson's Disease Trial

—"Disappointing" results from 3-year study don't back prior findings

by Elizabeth Hlavinka, Staff Writer, MedPage Today
May 02, 2019


https://www.medpagetoday.com/meetingcoverage/aan/79590


PHILADELPHIA -- An anti-hypertensive drug failed to outperform placebo in slowing Parkinson's disease progression, results from the highly-anticipated STEADY-PD III trial indicated.

No significant difference was seen after 36 months in average Unified Parkinson Disease Rating Scale (UPDRS) Part I-III scores measured in the ON state for patients receiving isradipine (DynaCirc) at 10 mg daily versus placebo (treatment effect 0.27 points, 95% CL -2.5 to 3.0, P=0.85), reported Tanya Simuni, MD, of the Northwestern University Feinberg School of Medicine, and colleagues.

Call on God but row away from the rocks.

-Hunter S. Thompson

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News